![Tocilizumab plus dexamethasone versus dexamethasone in patients with moderate-to-severe COVID-19 pneumonia: A randomised clinical trial from the CORIMUNO-19 study group - eClinicalMedicine Tocilizumab plus dexamethasone versus dexamethasone in patients with moderate-to-severe COVID-19 pneumonia: A randomised clinical trial from the CORIMUNO-19 study group - eClinicalMedicine](https://www.thelancet.com/cms/asset/48575ee5-15d9-46f7-9967-dbbe2d55eee3/gr1.jpg)
Tocilizumab plus dexamethasone versus dexamethasone in patients with moderate-to-severe COVID-19 pneumonia: A randomised clinical trial from the CORIMUNO-19 study group - eClinicalMedicine
![JCM | Free Full-Text | The Use of Tocilizumab in Patients with COVID-19: A Systematic Review, Meta-Analysis and Trial Sequential Analysis of Randomized Controlled Studies JCM | Free Full-Text | The Use of Tocilizumab in Patients with COVID-19: A Systematic Review, Meta-Analysis and Trial Sequential Analysis of Randomized Controlled Studies](https://pub.mdpi-res.com/jcm/jcm-10-04935/article_deploy/html/images/jcm-10-04935-g001-550.jpg?1635315302)
JCM | Free Full-Text | The Use of Tocilizumab in Patients with COVID-19: A Systematic Review, Meta-Analysis and Trial Sequential Analysis of Randomized Controlled Studies
![The sequence of disease-modifying anti-rheumatic drugs: pathways to and predictors of tocilizumab monotherapy | Arthritis Research & Therapy | Full Text The sequence of disease-modifying anti-rheumatic drugs: pathways to and predictors of tocilizumab monotherapy | Arthritis Research & Therapy | Full Text](https://media.springernature.com/lw685/springer-static/image/art%3A10.1186%2Fs13075-020-02408-4/MediaObjects/13075_2020_2408_Fig1_HTML.png)
The sequence of disease-modifying anti-rheumatic drugs: pathways to and predictors of tocilizumab monotherapy | Arthritis Research & Therapy | Full Text
![Effect of tocilizumab on clinical outcomes at 15 days in patients with severe or critical coronavirus disease 2019: randomised controlled trial | The BMJ Effect of tocilizumab on clinical outcomes at 15 days in patients with severe or critical coronavirus disease 2019: randomised controlled trial | The BMJ](https://www.bmj.com/content/bmj/372/bmj.n84/F1.medium.jpg)
Effect of tocilizumab on clinical outcomes at 15 days in patients with severe or critical coronavirus disease 2019: randomised controlled trial | The BMJ
![Cost-Effectiveness Analysis of Tocilizumab in Comparison with Infliximab in Iranian Rheumatoid Arthritis Patients with Inadequate Response to tDMARDs: A Multistage Markov Model - ScienceDirect Cost-Effectiveness Analysis of Tocilizumab in Comparison with Infliximab in Iranian Rheumatoid Arthritis Patients with Inadequate Response to tDMARDs: A Multistage Markov Model - ScienceDirect](https://ars.els-cdn.com/content/image/1-s2.0-S2212109915000709-gr1.jpg)
Cost-Effectiveness Analysis of Tocilizumab in Comparison with Infliximab in Iranian Rheumatoid Arthritis Patients with Inadequate Response to tDMARDs: A Multistage Markov Model - ScienceDirect
![Unravelling the potentialities of tocilizumab for the development of a potential immunotherapeutic regimen against COVID-19—A narrative review Unravelling the potentialities of tocilizumab for the development of a potential immunotherapeutic regimen against COVID-19—A narrative review](https://japsonline.com/admin/php/images/3505_images4.jpeg)
Unravelling the potentialities of tocilizumab for the development of a potential immunotherapeutic regimen against COVID-19—A narrative review
LncRNA MIR31HG is induced by tocilizumab and ameliorates rheumatoid arthritis fibroblast-like synoviocyte-mediated inflammation via miR-214-PTEN-AKT signaling pathway | Aging
![Tocilizumab Effect in COVID-19 Hospitalized Patients: A Systematic Review and Meta-Analysis of Randomized Control Trials Tocilizumab Effect in COVID-19 Hospitalized Patients: A Systematic Review and Meta-Analysis of Randomized Control Trials](https://www.fortunejournals.com/fulltext-images/tocilizumab-effect-in-covid19-hospitalized-patients-03.png)
Tocilizumab Effect in COVID-19 Hospitalized Patients: A Systematic Review and Meta-Analysis of Randomized Control Trials
![Tocilizumab Effect in COVID-19 Hospitalized Patients: A Systematic Review and Meta-Analysis of Randomized Control Trials Tocilizumab Effect in COVID-19 Hospitalized Patients: A Systematic Review and Meta-Analysis of Randomized Control Trials](https://www.fortunejournals.com/fulltext-images/tocilizumab-effect-in-covid19-hospitalized-patients-05.png)
Tocilizumab Effect in COVID-19 Hospitalized Patients: A Systematic Review and Meta-Analysis of Randomized Control Trials
![TropicalMed | Free Full-Text | Treatment of Severe COVID-19 with Tocilizumab Mitigates Cytokine Storm and Averts Mechanical Ventilation during Acute Respiratory Distress: A Case Report and Literature Review TropicalMed | Free Full-Text | Treatment of Severe COVID-19 with Tocilizumab Mitigates Cytokine Storm and Averts Mechanical Ventilation during Acute Respiratory Distress: A Case Report and Literature Review](https://www.mdpi.com/tropicalmed/tropicalmed-05-00112/article_deploy/html/images/tropicalmed-05-00112-g005.png)
TropicalMed | Free Full-Text | Treatment of Severe COVID-19 with Tocilizumab Mitigates Cytokine Storm and Averts Mechanical Ventilation during Acute Respiratory Distress: A Case Report and Literature Review
![Measuring IL-6 and sIL-6R in serum from patients treated with tocilizumab and/or siltuximab following CAR T cell therapy - ScienceDirect Measuring IL-6 and sIL-6R in serum from patients treated with tocilizumab and/or siltuximab following CAR T cell therapy - ScienceDirect](https://ars.els-cdn.com/content/image/1-s2.0-S0022175916300540-gr1.jpg)
Measuring IL-6 and sIL-6R in serum from patients treated with tocilizumab and/or siltuximab following CAR T cell therapy - ScienceDirect
![Tocilizumab among patients with COVID-19 in the intensive care unit: a multicentre observational study - The Lancet Rheumatology Tocilizumab among patients with COVID-19 in the intensive care unit: a multicentre observational study - The Lancet Rheumatology](https://www.thelancet.com/cms/attachment/a98a359c-8cbc-4a79-af8e-c4a9fb784347/gr1.gif)
Tocilizumab among patients with COVID-19 in the intensive care unit: a multicentre observational study - The Lancet Rheumatology
Tocilizumab reduces deaths in patients hospitalised with COVID-19 — Centre for Tropical Medicine and Global Health
![Pharmacokinetic /Pharmacodynamic Considerations of Alternate Dosing Strategies of Tocilizumab in COVID-19 | medRxiv Pharmacokinetic /Pharmacodynamic Considerations of Alternate Dosing Strategies of Tocilizumab in COVID-19 | medRxiv](https://www.medrxiv.org/content/medrxiv/early/2021/09/02/2021.08.28.21262692/F1.large.jpg)
Pharmacokinetic /Pharmacodynamic Considerations of Alternate Dosing Strategies of Tocilizumab in COVID-19 | medRxiv
![Comparing the efficacy of tocilizumab with corticosteroid therapy in treating COVID-19 patients: a systematic review and meta-analysis | SpringerLink Comparing the efficacy of tocilizumab with corticosteroid therapy in treating COVID-19 patients: a systematic review and meta-analysis | SpringerLink](https://media.springernature.com/lw685/springer-static/image/art%3A10.1007%2Fs40199-021-00430-8/MediaObjects/40199_2021_430_Figa_HTML.png)
Comparing the efficacy of tocilizumab with corticosteroid therapy in treating COVID-19 patients: a systematic review and meta-analysis | SpringerLink
![Comparison of the two tocilizumab strategies used in the economic model | Download Scientific Diagram Comparison of the two tocilizumab strategies used in the economic model | Download Scientific Diagram](https://www.researchgate.net/publication/237799717/figure/fig3/AS:669543773007881@1536643083282/Comparison-of-the-two-tocilizumab-strategies-used-in-the-economic-model.png)
Comparison of the two tocilizumab strategies used in the economic model | Download Scientific Diagram
![Single-cell analysis of two severe COVID-19 patients reveals a monocyte-associated and tocilizumab-responding cytokine storm | Nature Communications Single-cell analysis of two severe COVID-19 patients reveals a monocyte-associated and tocilizumab-responding cytokine storm | Nature Communications](https://media.springernature.com/lw685/springer-static/image/art%3A10.1038%2Fs41467-020-17834-w/MediaObjects/41467_2020_17834_Fig1_HTML.png)
Single-cell analysis of two severe COVID-19 patients reveals a monocyte-associated and tocilizumab-responding cytokine storm | Nature Communications
![Rapid Evidence Review: Tocilizumab in the management of patients who have severe COVID-19 infection with suspected hyperinflammation. [v6.0] Rapid Evidence Review: Tocilizumab in the management of patients who have severe COVID-19 infection with suspected hyperinflammation. [v6.0]](https://www.lenus.ie/bitstream/handle/10147/628004/COVID-19_Evidence_Review_Group_Tocilizumab_V6_Final_Version.pdf.jpg?sequence=8&isAllowed=y)